ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Adalimumab"

  • Abstract Number: L20 • 2019 ACR/ARP Annual Meeting

    A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naïve Patients with Active Psoriatic Arthritis: Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor Study Through 52 Weeks

    Josef Smolen1, Peter Nash 2, Hasan Tahir 3, Hendrik Schulze-Koops 4, Lingnan Li 5, Maja Hojnik 6, Amanda Gellett 5, Soyi Liu-Leage 7, Sreekumar Pillai 7 and Philip J. Mease 8, 1Medical University of Vienna, Vienna, Austria, 2Griffith University, Brisbane, Queensland, Australia, 3Royal Free London NHS Trust, London, United Kingdom, 4Department of Rheumatology/Clinical Immunology, Ludwig-Maximilians-University Munich, Munich, Germany, 5Eli Lilly and Company, Indianapolis, Indiana, 6Eli Lilly and Company, Indianapolis, IN, 7Eli Lilly and Company, Indianapolis, 8Swedish Medical Center and University of Washington, Seattle, Washington

    Background/Purpose: Multiple biologic DMARDs (bDMARDs) are available for treatment of PsA, but there are few direct comparisons of their efficacy and safety. Furthermore, efficacy of…
  • Abstract Number: 503 • 2019 ACR/ARP Annual Meeting

    A Pilot Phase 1, Randomized, Double-blind, Two-arm, Parallel Group, Single-dose Study to Evaluate the Safety and Pharmacokinetics of CT-P17 and Humira in Healthy Male Subjects

    Edward Keystone1, Daniel Furst 2, Malcolm Boyce 3, Frans van den Berg 3, SangJoon Lee 4, SungHyun Kim 4, YunJu Bae 4, GoEun Yang 4, JuHeon Koo 4, EunJin Choi 4 and Jonathan Kay 5, 1Mount Sinai Hospital, Toronto, Canada, 2University of California, Los Angeles, CA, 3Hammersmith Medicines Research, London, United Kingdom, 4Celltrion Inc., Incheon, Republic of Korea, 5UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA

    Background/Purpose: CT-P17 is a recombinant humanized monoclonal antibody that was developed as a biosimilar to the reference product, adalimumab. This was a first in human…
  • Abstract Number: 1407 • 2019 ACR/ARP Annual Meeting

    Baricitinib Provides Better Pain Relief Across All Disease Activity Levels Compared with Placebo and Adalimumab in Rheumatoid Arthritis

    Peter Taylor1, Janet Pope 2, Kei Ikeda 3, Xiang Zhang 4, Bochao Jia 4, Hong Zhang 5, Amanda Quebe 4, Yun-Fei Chen 4, Carol Gaich 4, Thorsten Holzkaemper 4, Anabela Cardoso 4 and Anthony Sebba 6, 1University of Oxford, Oxford, United Kingdom, 2Western University, London, ON, Canada, 3Chiba University Hospital, Chiba, Japan, 4Eli Lilly and Company, Indianapolis, IN, 5TechData Services, King of Prussia, PA, 6University of South Florida, Palm Harbor, FL

    Background/Purpose: In Phase 3 trial, RA-BEAM, baricitinib (BARI), a JAK1/JAK2 inhibitor, was associated with significant clinical improvements vs. placebo (PBO) and adalimumab (ADA) in RA…
  • Abstract Number: 1424 • 2019 ACR/ARP Annual Meeting

    The Effect of HLA-DRB1 Risk Alleles (Shared Epitope) on Changes in Immune Cell Subsets and Disease Activity Following Treatment with Abatacept versus Adalimumab in Seropositive Biologic-Naïve Patients with Early, Moderate-to-Severe RA: Data from a Head-to-Head Single-Blinded Trial

    Jane Buckner1, Vivian Bykerk 2, V. Michael Holers 3, S. Louis Bridges 4, William Rigby 5, Sheng Gao 6, Marleen Nys 7 and Neelanjana Ray 8, 1Benaroya Research Institute, Seattle, WA, 2Hospital for Special Surgery, New York City, NY, 3University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, 4University of Alabama at Birmingham, Birmingham, 5Dartmouth-Hitchcock Medical Center, Lebanon, 6Bristol-Myers Squibb, Princeton, NJ, 7Bristol-Myers Squibb, Braine L’Alleud, Belgium, 8Bristol-Myers Squibb, Princeton

    Background/Purpose: Mechanistic differences between biologic DMARDs are poorly understood. Exploring these mechanisms includes assessing the role of HLA-DRB1 alleles containing the shared epitope (SE), which…
  • Abstract Number: 1880 • 2019 ACR/ARP Annual Meeting

    Baricitinib 4 Mg and 2 Mg Once Daily Reduced Pain in Both Patients Who Were Opioid Users and Non-users in Active Rheumatoid Arthritis: A Post-hoc Analysis of Phase 3 Trials

    Janet Pope1, Yvonne Lee 2, Jeffrey Curtis 3, Daojun Mo 4, Terence Rooney 4, Li Xie 4, Christina Dickson 4, Douglas Schlichting 4, Amanda Quebe 4, Anabela Cardoso 4, Lee Simon 5 and Peter Taylor 6, 1Western University, London, ON, Canada, 2Northwestern University Feinberg School of Medicine, Chicago, 3University of Alabama at Birmingham, Birmingham, AL, 4Eli Lilly and Company, Indianapolis, IN, 5SDG LLC, Cambridge, MA, 6University of Oxford, Oxford, United Kingdom

    Background/Purpose: Opioid use in RA patients has increased over the past 2 decades in the US. Little is known about the combined effects of opioids…
  • Abstract Number: 2699 • 2019 ACR/ARP Annual Meeting

    Systemic Therapy in Children with Juvenile Idiopathic Arthritis-Associated Uveitis Immediately Following Failure of Methotrexate, Adalimumab and Infliximab

    Najima Mwase 1, Theresa Hennard 2, Joseph McDonald 3, Amy Cassedy 4, Onengiya Harry 3 and Sheila Angeles-Han5, 1Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Division of Rheumatology, Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, 3Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, 4Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, 5Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cinicinnati

    Background/Purpose: Juvenile idiopathic arthritis-associated uveitis (JIA-U) is the most common extra-articular manifestation of JIA, leading to ocular complications and blindness when not adequately treated. First…
  • Abstract Number: 2907 • 2019 ACR/ARP Annual Meeting

    Clinical and Functional Outcomes Among Rheumatoid Arthritis Patients Switching Between JAK1-Selective Inhibitor Upadacitinib and Adalimumab Following Insufficient Response

    Roy Fleischmann1, Mark Genovese 2, Ricardo Blanco 3, Stephen Hall 4, Glen Thomson 5, Filip Van den Bosch 6, Cristiano A. Zerbini 7, Jose Jeffrey Enejosa 8, Yihan Li 9, Ryan DeMasi 9 and In-Ho Song 8, 1Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, 2Stanford University, Stanford, CA, 3Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, 4Monash University and Emeritus Research, Melbourne, Australia, 5CIADS Research, Winnipeg, Canada, 6Ghent University Hospital, Ghent, Belgium, 7Centro Paulista de Investigação Clinica, São Paulo, Brazil, 8AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, 9AbbVie Inc., North Chicago, IL

    Background/Purpose: The goal of RA treatment is to achieve clinical remission or, at minimum, low disease activity (LDA). Modification of initial csDMARD therapy with the…
  • Abstract Number: 612 • 2018 ACR/ARHP Annual Meeting

    Anti-Drug Antibodies Detected By Competitive ELISA Can Predict Treatment Failure in Patients Taking Adalimumab

    Manca Ogrič1, Polona Žigon1, Katja Lakota1,2, Sonja Praprotnik1, David Drobne3,4, Borut Štabuc3,4, Snezna Sodin Semrl1,2 and Saša Čučnik1,5, 1University Medical Centre Ljubljana, Department of Rheumatology, Ljubljana, Slovenia, 2University of Primorska, Faculty of Mathematics, Natural Science and Information Technology, Koper, Slovenia, 3University Medical Centre Ljubljana, Department of Gastroenterology, Ljubljana, Slovenia, 4University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia, 5University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia

    Background/Purpose: A reduced clinical response in patients taking TNF-alpha inhibitors is influenced by their immunogenicity and therefore the importance of therapeutic drug monitoring has been…
  • Abstract Number: 2380 • 2018 ACR/ARHP Annual Meeting

    The Safety Profile of Adalimumab across Geographic Regions and Dosing Administrations Among Patients with Juvenile Idiopathic Arthritis Enrolled in a Registry

    Hermine I. Brunner1, Nicola Ruperto2, Kabita Nanda3, Mary Toth4, Ivan Foeldvari5, John F. Bohnsack6, Diana Milojevic7, Daniel J Kingsbury8, Katherine A. Marzan9, Elizabeth Chalom10, Gerd Horneff11, Rolf M. Kuester12, Jason A Dare13, Maria Trachana14, Mareike Bereswill15, Hartmut Kupper15, Daniel J Lovell16 and Alberto Martini2, 1PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Gaslini Institute and Pediatric Rheumatology International Trials Organisation, Genoa, Italy, 3Seattle Children's Hospital, Seattle, WA, 4Nemours Children’s Hospital, Orlando, FL, 5Hamburg Center for Pediatric and Adolescent Rheumatology, Hamburg, Germany, 6University of Utah, Salt Lake City, UT, 7Johns Hopkins All Children’s Hospital, St. Petersburg, FL, 8Randall Children’s Hospital, Portland, OR, 9Children's Hospital Los Angeles, Los Angeles, CA, 10The Pediatric Specialty Center at Saint Barnabas, West Orange, NJ, 11Asklepios Children's Clinic, Sankt Augustin, Germany, 12Orthopädiezentrum Altona, Hamburg, Germany, 13Arkansas Children’s Hospital, Little Rock, AR, 14Hippokration General Hospital, Aristotle University, Thessaloniki, Greece, 15AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 16PRCSG, Cincinnati Children’s Hospital Medical Center, Cinncinnati, OH

    Background/Purpose: Adalimumab (ADA) has been approved for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) with long-term use often required to maintain disease control. The…
  • Abstract Number: 2825 • 2018 ACR/ARHP Annual Meeting

    Reduction of Antidrug Antibody Levels after Switching to Rituximab in Patients with Rheumatoid Arthritis with Previous Failure to Infliximab or Adalimumab

    Ana Martínez1,2, Chamaida Plasencia2,3, Victoria Navarro-Compán2, Borja Hernández-Breijo2, Dora Pascual-Salcedo2, Pilar Nozal4, Cristina Diego4, Irene Monjo2,3, Laura Nuño3,5 and Alejandro Balsa2,6, 1Immunology. La Paz University Hospital, Madrid, Spain, 2Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain, 3Rheumatology, La Paz University Hospital, Madrid, Spain, 4La Paz University Hospital, Immunology, Madrid, Spain, 5Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, madrid, Spain, 6Hospital Universitario La Paz, Madrid, Spain

    Background/Purpose: Rituximab (Rtx) induces transient depletion of B cells. Previous data showed that Rtx is particularly effective on autoimmune diseases in which auto-antibodies (auto-Ab) are…
  • Abstract Number: 693 • 2018 ACR/ARHP Annual Meeting

    Combining Adalimumab with Methotrexate Does Not Improve Long Term Sustainability in Patients with Psoriatic Arthritis. Real World Evidence Report from the Quebec Database Rhumadata®

    Omar Benryane1, Louis Coupal2 and Denis Choquette2, 1Médecine, Faculté de Médecine de l’Université de Montréal, Montréal, QC, Canada, 2Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada

    Background/Purpose: Psoriatic Arthritis (PsA) in a musculoskeletal inflammatory condition associated with psoriasis. It has a heterogeneous set of clinical manifestations which include peripheral arthritis, axial…
  • Abstract Number: 2381 • 2018 ACR/ARHP Annual Meeting

    Long-Term Disease Control Among Patients with Juvenile Idiopathic Arthritis Receiving Adalimumab (Humira) Treatment for up to Six Years

    Daniel J Lovell1, Nicola Ruperto2, Andreas Reiff3, Lawrence Jung4, Katerina Jarosova5, Richard Mouy6, Isabelle Koné-Paut7, Olcay Y. Jones8, Veronika Vargova9, Carine Wouters10, Ivan Lagunes Galindo11, Carmen Mak12, Hermine I. Brunner13 and Alberto Martini2, 1Cincinnati Children’s Medical Center and Pediatric Rheumatology Collaborative Study Group Coordinating Center, Cincinnati, OH, 2Gaslini Institute and Pediatric Rheumatology International Trials Organisation, Genoa, Italy, 3Children's Hospital Los Angeles, Los Angeles, CA, 4Children’s National Health Systems, Washington, DC, 5Institute of Rheumatology, Prague, Czech Republic, 6Hôpital Necker-Enfants Malades, Paris, France, 7Bicetre Hospital, APHP, University of Paris Sud, Paris, France, 8Walter Reed National Military Medical Center, Bethesda, MD, 9Faculty Hospital, Kosice, Slovakia, 10University Hospital Gasthuisberg, Leuven, Belgium, 11AbbVie Inc., North Chicago, IL, 12AbbVie, North Chicago, IL, 13Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is a broad term that describes a clinically heterogeneous group of arthritides of unknown cause, which begin before 16 years…
  • Abstract Number: 890 • 2018 ACR/ARHP Annual Meeting

    A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib to Placebo and to Adalimumab, in Patients with Active Rheumatoid Arthritis with Inadequate Response to Methotrexate

    Roy Fleischmann1, Aileen L. Pangan2, Eduardo Mysler3, Louis Bessette4, Charles Peterfy5, Patrick Durez6, Andrew Ostor7, Yihan Li2, Yijie Zhou2, Ahmed A. Othman2, In-Ho Song8 and Mark C. Genovese9, 1University of Texas Southwestern Medical Center at Dallas, Metroplex Clinical Research Center, Dallas, TX, 2AbbVie, Inc., North Chicago, IL, 3Organización Medica de Investigación, Buenos Aires, Argentina, 4Laval University, Québec, QC, Canada, 5Spire Sciences LLC, Boca Raton, FL, 6Rheumatology, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, 7Cabrini Medical Center, Malvern, Australia, 8AbbVie, Inc., north chicago, IL, 9Stanford University Medical Center, Palo Alto, CA

    Background/Purpose: To assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib (UPA), a JAK1- selective inhibitor, vs placebo (PBO) and active comparator, originator…
  • Abstract Number: 2382 • 2018 ACR/ARHP Annual Meeting

    Real-World Safety and Effectiveness of Adalimumab in Patients with Juvenile Idiopathic Arthritis: Results from a Post-Marketing Surveillance in Japan

    Syuji Takei1, Naomi Iwata2, Ichiro Kobayashi3,4, Toru Igarashi5, Yoko Yoshinaga6, Naoko Matsubara7, Naomi Sunaga8, Ayumi Ito7 and Shumpei Yokota9, 1Department of Pediatrics, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan, 2Department of Immunology and Infectious Diseases, Aichi Children’s Health and Medical Center, Obu, Japan, 3Department of Allergy and Rheumatology, Chiba Children’s Hospital, Sapporo, Japan, 4Hokkaido University, Sapporo, Japan, 5Nippon Medical School, Tokyo, Japan, 6Evidence solution, Medical Communications, Medical, AbbVie GK, Tokyo, Japan, 7Medical, AbbVie GK, Tokyo, Japan, 8AbbVie GK, Tokyo, Japan, 9Fuji Toranomon Orthopedic Hospital, Gotemba, Japan

    Background/Purpose: The safety and efficacy of adalimumab (an anti-TNF-α antibody) treatment in patients with JIA have been demonstrated in clinical trials. This study was conducted…
  • Abstract Number: 1009 • 2018 ACR/ARHP Annual Meeting

    Monocytes Membrane TNF Expression and Anti-TNF Treatment in Rheumatoid Arthritis

    Audrey Paoletti1, Julien Rohmer2, Juliette Pascaud3, Bineta Oumouly1, Elodie Rivière3, Samuel Bitoun4, Gaetane Nocturne2 and Xavier Mariette5, 1U1184 IMVA, INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, le kremlin bicetre, France, 2INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, Le Kremlin Bicêtre, France, 3Immunology of viral Infections and Autoimmune Diseases, IDMIT, CEA - Université Paris Sud - INSERM U1184, Le Kremlin Bicêtre & Fontenay aux Roses, France, 4INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, le kremlin bicetre, France, 5Rheumatology department, Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique- Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, Paris, France

    Background/Purpose: Three monocyte subsets have been described based on their CD14 and CD16 expression profiles. The subpopulation CD14+CD16+ being expanded in rheumatoid arthritis (RA) patient.…
  • 1
  • 2
  • 3
  • …
  • 17
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology